Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.
Juan Cosín-Sales, Jose Polo-García, Olga Gavín Sebastián, Marta Rubio Cabezas, María Lloret Avellá
{"title":"Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.","authors":"Juan Cosín-Sales, Jose Polo-García, Olga Gavín Sebastián, Marta Rubio Cabezas, María Lloret Avellá","doi":"10.3389/fcvm.2025.1426072","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The use of vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) in Spain remains high, even though the available data on anticoagulation control (TRT, time in therapeutic range) shows suboptimal results. The objective of the AMFA project, an atlas of the management of anticoagulation in patients with AF, was to describe oral anticoagulation management in Spanish´ patients.</p><p><strong>Materials and methods: </strong>The AMFA Project is a descriptive, multicenter study. It included information from 60 healthcare areas from each of the 17 Spanish regions. Consensus methodologies were used to analyze qualitative information obtained from the physicians' experience and perception and quantitative data collected through a specialized study questionnaire. In this questionnaire, experts were asked to include data of the last 10 consecutive patients attended with AF on anticoagulation treatment.</p><p><strong>Results: </strong>Records from 1,580 patients were obtained from 176 experts. Of them, 34.7% were cardiologists, 32.9% general practitioners (GPs), and 32.4% hematologists. The utilization rates of Direct Oral Anticoagulants (DOACs) and VKAs in clinical practice was 55.8% and 43.3%, respectively, which was not correlated with experts' perception. Clinical practice data revealed that 30.3% of the patients included did not have international normalized ratio (INR) or TTR data available, while only 3.8% of the experts reported that INR/TTR information was not available according to their perception. Considering only patients who had INR and TTR available, clinical practice showed that 59.0% of the patients had their coagulation in range, while the remaining 41.0% were uncontrolled. This result matches with the general perception reported by the experts, 62.6% of patients in range. Additionally, up to 22.2% of patients received DOAC treatment at suboptimal doses.</p><p><strong>Conclusions: </strong>These data highlight the suboptimal control of the INR of patients, as well as the difficulties in DOACs access in Spain. The study uncovers the need to implement actions to improve INR control, facilitate access to DOACs treatment, and standardize AF patients' management. Establishing protocols that facilitate intervention may optimize the management of the patients with AF.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1426072"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919873/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1426072","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and objectives: The use of vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) in Spain remains high, even though the available data on anticoagulation control (TRT, time in therapeutic range) shows suboptimal results. The objective of the AMFA project, an atlas of the management of anticoagulation in patients with AF, was to describe oral anticoagulation management in Spanish´ patients.
Materials and methods: The AMFA Project is a descriptive, multicenter study. It included information from 60 healthcare areas from each of the 17 Spanish regions. Consensus methodologies were used to analyze qualitative information obtained from the physicians' experience and perception and quantitative data collected through a specialized study questionnaire. In this questionnaire, experts were asked to include data of the last 10 consecutive patients attended with AF on anticoagulation treatment.
Results: Records from 1,580 patients were obtained from 176 experts. Of them, 34.7% were cardiologists, 32.9% general practitioners (GPs), and 32.4% hematologists. The utilization rates of Direct Oral Anticoagulants (DOACs) and VKAs in clinical practice was 55.8% and 43.3%, respectively, which was not correlated with experts' perception. Clinical practice data revealed that 30.3% of the patients included did not have international normalized ratio (INR) or TTR data available, while only 3.8% of the experts reported that INR/TTR information was not available according to their perception. Considering only patients who had INR and TTR available, clinical practice showed that 59.0% of the patients had their coagulation in range, while the remaining 41.0% were uncontrolled. This result matches with the general perception reported by the experts, 62.6% of patients in range. Additionally, up to 22.2% of patients received DOAC treatment at suboptimal doses.
Conclusions: These data highlight the suboptimal control of the INR of patients, as well as the difficulties in DOACs access in Spain. The study uncovers the need to implement actions to improve INR control, facilitate access to DOACs treatment, and standardize AF patients' management. Establishing protocols that facilitate intervention may optimize the management of the patients with AF.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.